COMPANY

LYPHOMED, DIVISION OF FUJISAWA CANADA INC.

Name: LYPHOMED, DIVISION OF FUJISAWA CANADA INC. peptide roles
Creator: Global Peptide Index
License: https://globalpeptideindex.com/methodology

LYPHOMED, DIVISION OF FUJISAWA CANADA INC.: marketing authorisation holder for Oxytocin, Vancomycin, Vasopressin, as stated by public registers.

MARKETING AUTHORISATION HOLDER

Holds the licence to sell the medicine in a country (EMA, MHRA, Health Canada).

Oxytocin	OXYTOCIN INJ 10UNIT/ML USP (DIN 01944916), Cancelled Post Market Regulator Health Canada
Vancomycin	STERILE VANCOMYCIN HCL 5.0GM/VIAL (DIN 01990888), Cancelled Post Market Regulator Health Canada
Vancomycin	STERILE VANCOMYCIN HCL USP 1.0GM/VIAL (DIN 01990861), Cancelled Post Market Regulator Health Canada
Vancomycin	STERILE VANCOMYCIN HCL USP 500MG/VIAL (DIN 01990853), Cancelled Post Market Regulator Health Canada
Vasopressin	VASOPRESSIN INJ 20UNIT/ML USP (DIN 01944800), Marketed Regulator Health Canada

What a register states, not an endorsement or an accusation by this site. All companies.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.